Uiuce bus model

From 2013.igem.org

(Difference between revisions)
 
(74 intermediate revisions not shown)
Line 18: Line 18:
body{
body{
   color: #34495e;
   color: #34495e;
 +
  width: 1000px;
 +
  margin: 0 auto;
}
}
#bodyContent h1, #bodyContent h2{
#bodyContent h1, #bodyContent h2{
Line 66: Line 68:
/*the nav settings
/*the nav settings
----------------------------------------------- */
----------------------------------------------- */
 +
ul.navbar-nav{margin: 0 -35px 25px 0;float: right;}
.navbar-inverse .navbar-nav>.open>a, .navbar-inverse .navbar-nav>.open>a:hover, .navbar-inverse .navbar-nav>.open>a:focus{
.navbar-inverse .navbar-nav>.open>a, .navbar-inverse .navbar-nav>.open>a:hover, .navbar-inverse .navbar-nav>.open>a:focus{
   color: #1abc9c;
   color: #1abc9c;
Line 348: Line 351:
     <div class="collapse navbar-collapse navbar-ex1-collapse">
     <div class="collapse navbar-collapse navbar-ex1-collapse">
       <ul class="nav navbar-nav pull-right">
       <ul class="nav navbar-nav pull-right">
-
       <li><a href="https://2013.igem.org/Team:UIUC_Entrepreneurs">Home</a></li>
+
       <li><a href="https://2013.igem.org/Team:UIUC_Entrepreneurs"><font size="5"><b>Home</b></font></a></li>
-
            <li class="dropdown" role="menu" aria-labelledby="dropdownMenu">
+
    <li><a href="https://2013.igem.org/Uiuce_bus_model"><font size="5"><b>Business Model</b></font></a></li>
-
              <a class="dropdown-toggle" data-toggle="dropdown" href="#">Business Model<b class="caret"></b></a>
+
      <li><a href="https://2013.igem.org/Uiuce_modulab"><font size="5"><b>ModuLab</b></font></a></li>
-
              <ul class="dropdown-menu">
+
-
          <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/UIUCe_competitive_analysis">Competitive Analysis</a></li>
+
-
                  <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_market_pen">Market Penetration Strategy</a></li>
+
-
                  <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_market_plan">Marketing Plan</a></li> 
+
-
                <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_financial_plan">Financial Plan</a></li>
+
-
               
+
-
                <ul class="dropdown-menu">
+
-
                        <li><a tabindex="-1" href="https://2013.igem.org/Team:OUC-China/Review">How</a></li>
+
-
                        <li><a tabindex="-1" href="https://2013.igem.org/Team:OUC-China/Design">Do</a></li>
+
-
              <li><a tabindex="-1" href="https://2013.igem.org/Team:OUC-China/Microfluidics">You</a></li>
+
-
              <li><a tabindex="-1" href="https://2013.igem.org/Team:OUC-China/Results">Like</a></li>
+
-
                </ul>
+
-
            </li>
+
-
               
+
-
               
+
-
          <ul class="dropdown-menu">
+
-
                      <li><a tabindex="-1" href="https://2013.igem.org/Team:OUC-China/Introduction">These</a></li>
+
-
                      <li><a tabindex="-1" href="https://2013.igem.org/Team:OUC-China/RNA guardian/Design">Subtabs</a></li>
+
-
            <li><a tabindex="-1" href="https://2013.igem.org/Team:OUC-China/RNA guardian/Results">Here</a></li>
+
-
            <li><a tabindex="-1" href="https://2013.igem.org/Team:OUC-China/Reference">?</a></li>
+
-
            </ul>
+
-
          </li>
+
-
          <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_risk_analysis">Risk Analysis</a></li>
+
-
          <li role="presentation"><a role="menuitem" tabindex="-1" href="/*PUT A URL HERE IF YOU WANT IT*/">An Extra Tab for now</a></li>
+
-
                </ul>
+
-
            </li>
+
-
            <li class="dropdown" role="menu" aria-labelledby="dropdownMenu">
+
-
           
+
-
                <ul class="dropdown-menu">
+
-
                  <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Team:OUC-China/Magnetic Analysis">Magnetic Analysis</a></li>
+
-
                  <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Team:OUC-China/Model in RNA guardian">Model in RNA guardian</a></li>
+
-
                </ul>
+
-
            </li>
+
            
            
-
      <li class="dropdown">
+
   
-
              <a class="dropdown-toggle" data-toggle="dropdown" href="#">ModuLab<b class="caret"></b></a>
+
           
-
               <ul class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu">
+
       
-
                  <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_why">Why?</a></li>
+
                
-
                  <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_what">What?</a></li>
+
     
-
                  <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_how">How?</a></li>
+
              
-
          <li role="presentation"><a role="menuitem" tabindex="-1" href="/*PUT A URL HERE IF YOU WANT IT">Extra Tab</a></li>
+
-
          <li role="presentation"><a role="menuitem" tabindex="-1" href="/*PUT A URL HERE IF YOU WANT IT*/">Or two...</a></li>
+
-
        </ul>
+
-
             </li>
+
      
      
       <li class="dropdown">
       <li class="dropdown">
-
                 <a class="dropdown-toggle" data-toggle="dropdown" href="#">About Us<b class="caret"></b></a>
+
                 <a class="dropdown-toggle" data-toggle="dropdown" href="#"><font size="5"><b>About Us</b></font><b class="caret"></b></a>
                 <ul id="menu2" class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu">
                 <ul id="menu2" class="dropdown-menu" role="menu" aria-labelledby="dropdownMenu">
-
                          <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_our_mission">Our MIssion</a></li>
 
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Igeme_team">Our Team</a></li>
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Igeme_team">Our Team</a></li>
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_advisory_board">Advisory Board</a></li>
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_advisory_board">Advisory Board</a></li>
-
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://2013.igem.org/Uiuce_igeme">iGEMe</a></li>
+
                           <li role="presentation"><a role="menuitem" tabindex="-1" href="https://igem.org/Main_Page">iGEM</a></li>
                          
                          
_TOC_             
_TOC_             
Line 412: Line 377:
</div>     
</div>     
<!--the slidershow begin-->
<!--the slidershow begin-->
-
<div class="banner">
+
 
-
      <ul>
+
-
        <li style="background-image: url('https://static.igem.org/mediawiki/2013/e/e8/Smiling_fox.jpg');">
+
-
          <div class="inner">
+
-
         
+
-
         
+
-
           
+
-
          </div>
+
-
        </li>
+
        
        
-
      </ul>
+
   
-
  </div>
+
   <!--the slidershow end-->
   <!--the slidershow end-->
-
<pre>[[#Com An]]</pre>
+
 
-
===Com An===
+
        <left><h3><b>Business Model</b></h3><hr></left>
-
 
+
-
<div class="container">
+
-
        <h3><b>Competitive Analysis</b></h3><hr>
+
-
        <p>Text about Comp An here</p>
+
          
          
 +
 +
 +
</div>
</div>
-
<!--KYOTO CODE-->
 
-
<div class="document">
 
-
  <div id="doc-left">
 
-
  <ul class="nav metro-nav-list">
 
-
  <li class="nav-header">PROJECT</li>
 
-
  <li class="">
 
-
      <a href="#Overview">Project Overview</a>
 
-
      <ul class="nav">
 
-
      </ul>
 
-
  </li>
 
-
  <li class="">
 
-
      <a href="#Results">Results</a>
 
-
      <ul class="nav">
 
-
        <li><a href="#1,SDS-PAGE">1,SDS-PAGE</a></li>
 
-
        <li><a href="#2, Growth Curves">2, Growth Curves</a></li>
 
-
        <li><a href="#3, Bioassay using Drosophila">3, Bioassay using Drosophila</a></li>
 
-
          <li><a href="#4,The comparing with the ability of ATF1 and ATF2">4,The comparing with the ability of ATF1 and ATF2</a></li>
 
-
      </ul>
 
-
  </li>
 
-
  <li class="">
+
<center><font size="3"><b> Business Overview</b></font><br></center>
-
      <a href="#Future">Future</a>
+
<p><b>Customer Problem</b></p><br>
-
      <ul class="nav">
+
<p>The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.</p><br>
-
      </ul>
+
-
  </li>
+
-
  </ul>
+
<center><img src="https://static.igem.org/mediawiki/2013/e/ec/Uiuce_Igeme_customer_prob.png" width="400" height="294" alt="Pills" /></center><br><br>
-
  </div>
+
-
<div id="Overview" style="margin-top:-50px; padding-top:50px;" >
+
-
<h2>Project Overview</h2>
+
-
<p>We are trying to construct a novel E.coli that has fruity flavor like Japanese rice wine (Japanese sake). In order to accomplish the purpose, yeast genes related with production of the Japanese sake fragrance were introduced into E. coli cells. We also tried to develop a way to eliminate bad smells of E. coli in parallel. Although we previously won a gold prize by the development of a novel pen (E. coli Pen) in 2010, its bad smells were weak points and must be improved. We will overcome this problem through the progress of our new project in 2013. So far, “smell” is not a popular keyword and not a major field in iGEM. However, we believe that our project will provide a new point of view to iGEM friends.</p>
+
-
</div>
+
<p><b>Our Solution</b></p><br>
 +
<p>Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.</p><br><br><br>
-
<div id="Results" style="margin-top:-50px; padding-top:50px;">
+
<center><font size="3"><b> Competitive Analysis</b></font><br></center>
-
<h2>Results</h2>
+
-
<h3 id="1,SDS-PAGE" style="margin-top:-70px; padding-top:70px;" >
+
<p><b>Direct Competition</b></p><br>
-
<p><b><font size="5">1,SDS-PAGE</font></b></p></h3>
+
<p>Because of the relative youth of synthetic biology, there are currently no products that are able to fully conduct the cloning protocol from start to finish without human intervention. We could, however, experience competition from device manufacturers that produce some of the individual components of our system. As per our own research, the closest product to ModuLab is the Freedom EVO® Expression Workstation produced by Tecan Group Ltd.</p>
-
<p>We constructed ATF2 generator. (BBa_K1049002) Our team KIT-Kyoto 2013 constructed this part for the purpose of measurement. T7 promoter is an IPTG-inducible promoter. We added 20µL IPTG (100mM) to our genetically modified E.coli after cultivation at 28 and 37 ˚C. 2 hours after, we extracted soluble proteins from it by FastBreak™ Cell Lysis Reagent and did SDS-polyacrylamide gel electrophoresis.</p>
+
-
            <div class="thumbnail"  style="width:800px; margin: 0 auto;" >
+
<center><img src="https://static.igem.org/mediawiki/2013/8/82/Uiuce_direct_comp.png" width="720" height="294" alt="Pills" /><br><br></center>
-
              <img src="https://static.igem.org/mediawiki/parts/9/98/KIT2013SDS.png" alt=""/ width="550px" >
+
-
              <div class="caption">
+
-
                 
+
-
              </div>
+
-
            </div>
+
-
<br>
+
-
<p>ATF2 gene encodes AATase, which is about 62kDa. The consumption of protein marker is like this.</p>
+
-
<p>Myosin 200kDa β‐Galactosidase 120kDa Bovine Serum Albumin 95kDa Glutamine dehydrogenase 68kDa Ovalbumin 50kDa Carbonic Anhydrase 36kDa Myoglobin 27kDa Lysozyme 20kDa Aprotinin 10kDa</p>
+
-
<p>You can find the band at lanes which are added IPTG just beneath the band of 68kDa.</p>
+
-
<br>
+
 +
<p><b>Indirect Competition</b></p>
 +
<p>Indirect competition to the field of synthetic biology as a whole is high, given other technologies that have been around for decades. In the specific niche market within which Vivosynth is positioned, however, such competition is negligible, because of the relative nonexistence of methods to fully automate the cloning protocol.</p><br>
-
<h3 id="2, Growth Curves" style="margin-top:-70px; padding-top:70px;" >
+
<p><b>Future Competition </b></p>
-
<p><b><font size="5">2,Growth curves</font></b></p></h3>
+
<p>Future competition will likely come in the form of new advances in robotics and automation that will further optimize cloning. Vivosynth is uniquely suited to adapting to these new advances because of our close ties to the University of Illinois and our ability to modify our product(s) as and when it needs </p><br>
-
<p>We measured the turbidities of the transformants every 2 hour and made the growth curves. We transferred the transformant prepared to 100 mL flasks and add 660uL IPTG and 108uL isoamyl alcohol to them after 2 hours of the start. We measured the turbidities every 2 hour. The measurements were carried out for 12 hours.</p>
+
-
<p>LB　100mL</p>
+
-
<p>ampicillin　150uL</p>
+
-
<p>sample 50uL</p>
+
-
<p>IPTG 660uL</p>
+
-
<p>isoamyl alcohol 108uL</p>
+
-
+
-
<p>37°C, 125/min</p>
+
-
            <div class="thumbnail"  style="width:560px; margin: 0 auto;" >
+
<p><b> Competitive Advantage</b></p><br>
-
              <img src="https://static.igem.org/mediawiki/2013/4/41/Growth_atf2.png" alt=""/ width="550px" >
+
<p>Our product, ModuLab, would be unique in its ability to conduct the entire cloning protocol from start to finish without human intervention. As far as we know, there are no products capable of doing this. We believe such a product would dramatically increase the rate at which synthetic biology research and manufacturing progresses over the next decade. The product is also unique because it will be able to adapt to automate any lab machinery.</p><br><br>
-
            </div>
+
-
<p>In addition, we measured the turbidities of the transformants without adding IPTG and isoamyl alcohol too.
+
-
We measured 4 samples; ATF2-pET-15b, ATF2-pET-15b + IPTG, empty pET-15b, empty pET-15b + IPTG.</p>
+
-
+
-
<p>As the result, ATF2-pET-15b transformants grow well relative to control(transformants having empty pET-15b vector).
+
-
We propose the folllowing hypothesis.
+
-
Isoamyl acetate indicates a stimulatory effect of growth on E.coli cells when compared to isoamyl alcohol so that transformants having ATF2-pET-15b grow well relative to control.</p>
+
-
<p>And ATF2-pET-15b without IPTG grow well relative to ATF2-pET-15b add IPTG. It is explained by the following hypothesis.
+
-
When we add IPTG to the transformant having ATF2-pET-15b, ATF2 protein (AATase) is expessed in bulk in the transformant. A massive amount of AATase has a potential to surpress the growth.</p>
+
-
+
 +
<center><font size="3"><b> Market Analysis</b></font><br></center>
 +
<p><b>Industry Profile</b></p><br>
 +
<p>The global synthetic biology market is estimated to grow to $4.5 billion over the next three years. This is due to major developments in biomedicine, pharmaceutical drug synthesis, energy and environmental research, biomaterials, nanotechnology, and biosecurity. There have been significant investments in the industry by companies such as Amyris Inc, GeneScript, Bayer, and Blue Heron Biotechnologies. Additionally, developments in DNA synthesis and sequencing technologies and bioinformatics have catalyzed the progress of synthetic biology ever since the creation of the first synthetic cell in 2010. Synthetic biology is being recognized around the world as an emerging technology that has the potential to provide solutions to energy and food shortage, pollution, infectious diseases, and even climate change. The following diagram depicts the distribution of the global synthetic biology market share, as of 2011:</p><br><br>
-
<h3 id="3, Bioassay using Drosophila" style="margin-top:-70px; padding-top:70px;" >
+
<center><img src="https://static.igem.org/mediawiki/2013/4/4c/Uiuce_industrial_prof.png" width="500" height="294" alt="Pills" /><br><br></center>
-
<p><b><font size="5">3, Bioassay using Drosophila</font></b></p></h3>
+
-
<p>Next, to confirm the activity of AATase, we added isoamyl alcohol after IPTG induction and cultivated for about 2 hours. We used E. coli cells carrying the empty vector (pET-15b) as a control and compare it with the E.coli cells carrying pET15b-ATF2 after addition of isoamyl alcohol. To compare the production of isoamyl acetate, we carried out a bioassay using Drosophila. Because Drosophila favors the fruit odor like isoamyl acetate. [1]</p>
+
-
<p>After the addition of IPTG and isoamyl acetate, the culture was impregnated into the filter and placed in a case containing 10 Drosophilas. We monitored the behavior of Drosophila. This is the result. For 1 hour, 7 flies gathered to the ATF2. These results clearly indicate that ATF2 produces isoamyl acetate from isoamyl alcohol.</p>
+
<p><b>Marketing Strategy</b></p>
 +
<p>Vivosynth will adopt a two-step marketing plan for commercializing ModuLab. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price system. Intellectual property protection for our design will be obtained prior to the execution of our sales strategy.<br><br>
-
            <div class="thumbnail"  style="width:560px; margin: 0 auto;" >
+
Next, the company will look to enter into distribution agreements for the registration and sales of its products in the United States, and eventually foreign countries. These distribution agreements will take the form of contracts with existing manufacturers of biotechnology devices, in order to achieve economies of scale. <br><br>
-
              <img src="https://static.igem.org/mediawiki/2013/e/e7/ATF2result_htm_m7be19f37.png" alt=""/ width="550px" >
+
-
            </div>
+
-
<div class="thumbnail"  style="width:560px; margin: 0 auto;" >
+
-
              <img src="https://static.igem.org/mediawiki/2013/1/1f/The_number_of_fly.jpg" alt=""/ width="550px" >
+
-
            </div>
+
-
<p>This is the result. For 1 hour, 7 flies gathered to the ATF2. These results clearly indicate that ATF2 produces isoamyl acetate from isoamyl alcohol.</p>
+
-
<br>
+
Vivosynth will also actively pursue online advertising, advertise our products at biotechnology oriented trade shows, and release a monthly newsletter to keep potential and current customers updated about product developments.<br><br>
-
<br>
+
-
<h3 id="4,The comparing with the ability of ATF1 and ATF2"  style="margin-top:-70px; padding-top:70px;" >
+
-
<p><b><font size="5">4,The comparing with the ability of ATF1 and ATF2</font></b></p></h3>
+
-
<p>In addition, according to the previous study [2], the ability of ATF2 protein to produce isoamyl acetate in yeast is higher than that of ATF1 protein.</p>
+
-
<p>It is known that both ATF1 and ATF2 protein are involved in producing isoamyl acetate.</p>
+
<center><img src="https://static.igem.org/mediawiki/2013/3/37/Uiuce_marketing.png" width="720" height="294" alt="Pills" /><br><br><br><br></center>
-
            <div class="thumbnail"  style="width:560px; margin: 0 auto;" >
+
-
              <img src="https://static.igem.org/mediawiki/parts/d/d5/Earlystudy.png" alt=""/ width="550px" >
+
-
            </div>
+
-
<p>In 2006, MIT iGEM team submitted ATF1 coding sequence. (BBa_J45006) Our new part, ATF2 coding sequence, fall under the category of the improvement of function existing BioBrick Part, BBa_J45006. Herewith, our team, KIT-Kyoto 2013 iGEM team, meets the additional requirements for a Gold Medal.</p>
+
-
<br><br>
 
 +
<center><font size="3"><b> Past and Projected Timeline</b></font><br></center>
 +
<p>Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.</p>
 +
 +
<center><img src="https://static.igem.org/mediawiki/2013/5/5b/Uiuce_timeline.png" width="720" height="294" alt="Pills" /><br><br><br><br><br></center>
 +
 +
 +
<center><font size="3"><b>Financial Plan</b></font><br></center><br><br>
 +
 +
<center><img style="-webkit-user-select: none" src="https://static.igem.org/mediawiki/2013/9/9f/Uiuce_table_edit.png"></center>
 +
 +
 +
 +
 +
<center><font size="3"><b>Vivosynth Technologies: Value Proposition</b></font><br></center>
 +
<br><br>
-
</div>
 
-
<!--END KYOTO CODE-->
 
 +
<center><img src="https://static.igem.org/mediawiki/2013/c/c2/Uiuce_Capture2.PNG" width="720" height="294" alt="Pills" /></center>
<!--footer-->
<!--footer-->

Latest revision as of 03:53, 29 October 2013

Business Model
Business Overview

Customer Problem


The cloning process consists of several individual steps, each with its own equipment and machinery. It is complex, yet still requires a remarkable amount of human intervention. This results in errors, inconsistencies, and an overall delay in meeting significant synthetic biology milestones. Our team seeks to minimize this “human intervention” element by designing, prototyping, and commercializing an automated cloning system.


Pills


Our Solution


Our flagship product, ModuLab, is an automated system designed to optimize cloning, the underlying process of synthetic biology. The ultimate goals of ModuLab are to minimize error, maximize efficiency and provide synthetic biologists with feedback on every stage of the cloning process.




Competitive Analysis

Direct Competition


Because of the relative youth of synthetic biology, there are currently no products that are able to fully conduct the cloning protocol from start to finish without human intervention. We could, however, experience competition from device manufacturers that produce some of the individual components of our system. As per our own research, the closest product to ModuLab is the Freedom EVO® Expression Workstation produced by Tecan Group Ltd.

Pills

Indirect Competition

Indirect competition to the field of synthetic biology as a whole is high, given other technologies that have been around for decades. In the specific niche market within which Vivosynth is positioned, however, such competition is negligible, because of the relative nonexistence of methods to fully automate the cloning protocol.


Future Competition

Future competition will likely come in the form of new advances in robotics and automation that will further optimize cloning. Vivosynth is uniquely suited to adapting to these new advances because of our close ties to the University of Illinois and our ability to modify our product(s) as and when it needs


Competitive Advantage


Our product, ModuLab, would be unique in its ability to conduct the entire cloning protocol from start to finish without human intervention. As far as we know, there are no products capable of doing this. We believe such a product would dramatically increase the rate at which synthetic biology research and manufacturing progresses over the next decade. The product is also unique because it will be able to adapt to automate any lab machinery.



Market Analysis

Industry Profile


The global synthetic biology market is estimated to grow to $4.5 billion over the next three years. This is due to major developments in biomedicine, pharmaceutical drug synthesis, energy and environmental research, biomaterials, nanotechnology, and biosecurity. There have been significant investments in the industry by companies such as Amyris Inc, GeneScript, Bayer, and Blue Heron Biotechnologies. Additionally, developments in DNA synthesis and sequencing technologies and bioinformatics have catalyzed the progress of synthetic biology ever since the creation of the first synthetic cell in 2010. Synthetic biology is being recognized around the world as an emerging technology that has the potential to provide solutions to energy and food shortage, pollution, infectious diseases, and even climate change. The following diagram depicts the distribution of the global synthetic biology market share, as of 2011:



Pills

Marketing Strategy

Vivosynth will adopt a two-step marketing plan for commercializing ModuLab. It involves the systematic dissemination of our technologies to academic and research institutions at highly discounted rates, followed by the targeted selection of pharmaceutical companies and chemical manufacturers with our final full-price system. Intellectual property protection for our design will be obtained prior to the execution of our sales strategy.

Next, the company will look to enter into distribution agreements for the registration and sales of its products in the United States, and eventually foreign countries. These distribution agreements will take the form of contracts with existing manufacturers of biotechnology devices, in order to achieve economies of scale.

Vivosynth will also actively pursue online advertising, advertise our products at biotechnology oriented trade shows, and release a monthly newsletter to keep potential and current customers updated about product developments.

Pills



Past and Projected Timeline

Our business model has currently been implemented through the model creation phase. Next steps include cultivating relationships and licensing our technology to existing biotechnology device manufacturers.

Pills




Financial Plan


Vivosynth Technologies: Value Proposition


Pills

Retrieved from "http://2013.igem.org/Uiuce_bus_model"